OXBRYTA
- Product NDC
- 72786-111
- Requested package NDC
- 72786-111-02
- 11-digit product format
- 727860111
- Labeler code
- 72786
- Product ID
- 72786-111_e27a3e07-438e-49d3-aae3-095e9379c7b4
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Voxelotor
- Dosage form
- TABLET, FOR SUSPENSION
- Route
- ORAL
- Labeler
- Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
- Application
- NDA216157
- Marketing category
- NDA
- Marketing start
- 2021-12-17
- Substance
- VOXELOTOR
- Active strength
- 300 mg/1
- Pharmacologic classes
- Cytochrome P450 3A4 Inhibitors [MoA], Hemoglobin S Polymerization Inhibitor [EPC], Hemoglobin S Polymerization Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N216157-001 | OXBRYTA | VOXELOTOR | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N216157-001 | 10017491 | 2032-12-28 | Drug product | 2022-01-14 | |
| N216157-001 | 10034879 | 2032-12-28 | Drug substance, Drug product | 2022-01-14 | |
| N216157-001 | 10806733 | 2032-12-28 | Drug substance | 2022-01-14 | |
| N216157-001 | 9018210 | 2033-11-25 | Drug substance, Drug product | 2022-01-14 | |
| N216157-001 | 9248199 | 2034-01-29 | U-2676 | 2022-01-14 | |
| N216157-001 | 9248199 | 2034-01-29 | U-2715 | 2022-01-14 | |
| N216157-001 | 10722502 | 2035-02-06 | Drug product | 2022-01-14 | |
| N216157-001 | 11452720 | 2035-02-06 | U-3459 | 2022-10-27 | |
| N216157-001 | 9447071 | 2035-02-06 | Drug substance, Drug product | 2022-01-14 | |
| N216157-001 | 11020382 | 2036-12-02 | U-3133 | 2022-01-14 | |
| N216157-001 | 11020382 | 2036-12-02 | U-3134 | 2022-01-14 | |
| N216157-001 | 11944612 | 2036-12-02 | U-3893 | 2024-05-02 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N216157-001 | ODE* | 2026-11-25 |
| N216157-001 | ODE-394 | 2028-12-17 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 4b0b4de00fa7… | |
| 2022-03-09 01:35 UTC | 2022-03 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | bb7c543d1eb4… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD, RS | 2021-12-17 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N216157-001 | OXBRYTA | 300MG | TABLET, FOR SUSPENSION / ORAL | RLD | 2021-12-17 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 10017491 | 2032-12-28 | Drug product | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 10034879 | 2032-12-28 | Drug substance, Drug product | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 10806733 | 2032-12-28 | Drug substance | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 9018210 | 2033-11-25 | Drug substance, Drug product | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 9248199 | 2034-01-29 | U-2676 | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 9248199 | 2034-01-29 | U-2715 | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 10722502 | 2035-02-06 | Drug product | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 11452720 | 2035-02-06 | U-3459 | 2022-10-27 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 9447071 | 2035-02-06 | Drug substance, Drug product | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 11020382 | 2036-12-02 | U-3133 | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 11020382 | 2036-12-02 | U-3134 | 2022-01-14 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | 11944612 | 2036-12-02 | U-3893 | 2024-05-02 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 10017491 | 2032-12-28 | Drug product | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 10034879 | 2032-12-28 | Drug substance, Drug product | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 10806733 | 2032-12-28 | Drug substance | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 9018210 | 2033-11-25 | Drug substance, Drug product | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 9248199 | 2034-01-29 | U-2676 | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 9248199 | 2034-01-29 | U-2715 | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 10722502 | 2035-02-06 | Drug product | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 11452720 | 2035-02-06 | U-3459 | 2022-10-27 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 9447071 | 2035-02-06 | Drug substance, Drug product | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 11020382 | 2036-12-02 | U-3133 | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 11020382 | 2036-12-02 | U-3134 | 2022-01-14 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | 11944612 | 2036-12-02 | U-3893 | 2024-05-02 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 10017491 | 2032-12-28 | Drug product | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 10034879 | 2032-12-28 | Drug substance, Drug product | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 10806733 | 2032-12-28 | Drug substance | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 9018210 | 2033-11-25 | Drug substance, Drug product | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 9248199 | 2034-01-29 | U-2676 | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 9248199 | 2034-01-29 | U-2715 | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 10722502 | 2035-02-06 | Drug product | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 11452720 | 2035-02-06 | U-3459 | 2022-10-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 9447071 | 2035-02-06 | Drug substance, Drug product | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 11020382 | 2036-12-02 | U-3133 | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 11020382 | 2036-12-02 | U-3134 | 2022-01-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | 11944612 | 2036-12-02 | U-3893 | 2024-05-02 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | 10017491 | 2032-12-28 | Drug product | 2022-01-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | 10034879 | 2032-12-28 | Drug substance, Drug product | 2022-01-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | 10806733 | 2032-12-28 | Drug substance | 2022-01-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | 9018210 | 2033-11-25 | Drug substance, Drug product | 2022-01-14 | caaa826d4ba7… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | ODE* | 2026-11-25 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N216157-001 | ODE-394 | 2028-12-17 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | ODE* | 2026-11-25 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N216157-001 | ODE-394 | 2028-12-17 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | ODE* | 2026-11-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N216157-001 | ODE-394 | 2028-12-17 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | ODE* | 2026-11-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N216157-001 | ODE-394 | 2028-12-17 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N216157-001 | ODE* | 2026-11-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N216157-001 | ODE-394 | 2028-12-17 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N216157-001 | ODE* | 2026-11-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N216157-001 | ODE-394 | 2028-12-17 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N216157-001 | ODE-394 | 2028-12-17 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N216157-001 | ODE-394 | 2028-12-17 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N216157-001 | ODE-394 | 2028-12-17 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N216157-001 | NCE | 2024-11-25 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N216157-001 | ODE-394 | 2028-12-17 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N216157-001 | NCE | 2024-11-25 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N216157-001 | ODE-394 | 2028-12-17 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N216157-001 | NCE | 2024-11-25 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N216157-001 | ODE-394 | 2028-12-17 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N216157-001 | NCE | 2024-11-25 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N216157-001 | ODE-394 | 2028-12-17 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N216157-001 | NCE | 2024-11-25 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N216157-001 | ODE-394 | 2028-12-17 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N216157-001 | NCE | 2024-11-25 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N216157-001 | ODE-394 | 2028-12-17 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N216157-001 | NCE | 2024-11-25 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N216157-001 | ODE-394 | 2028-12-17 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N216157-001 | NCE | 2024-11-25 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N216157-001 | ODE-394 | 2028-12-17 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N216157-001 | NCE | 2024-11-25 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | N216157-001 | ODE-394 | 2028-12-17 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N216157-001 | NCE | 2024-11-25 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N216157-001 | NCE | 2024-11-25 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N216157-001 | NCE | 2024-11-25 | 4b0b4de00fa7… |
| 2022-03-09 01:35 UTC | 2022-03 | N216157-001 | NCE | 2024-11-25 | bb7c543d1eb4… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N216157-001 | NCE | 2024-11-25 | 6a51e52b5d6a… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N216157-001 | ODE-394 | 2028-12-17 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N216157-001 | NCE | 2024-11-25 | 1c564ffb4f44… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- OXBRYTA
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| VOXELOTOR | 300 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 3ZO554A4Q8 | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 3c557fac-29ec-483f-b691-8a935d4decc3 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 362d7abb-94e6-4c60-9a58-266894157713 | Product name | 1 | 20231023 |
| f462aae3-6ca5-4ac1-bbf8-920d1164ae0a | Product name | 2 | 20220720 |
| 816b97af-edc5-4060-aff1-b814bdbcad50 | Product name | 1 | 20190415 |
| 419aab54-5d5a-4146-9453-026d4a9991be | Product name | 2 | 20170525 |
| 89dac932-b90a-4410-9ab1-84c53e57de25 | Product name | 1 | 20150316 |
| d723478e-ad4a-ec23-6bd7-cfe33e1e3840 | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 72786-111-02 | OXBRYTA | 60 in 1 BOTTLE, PLASTIC | TABLET, FOR SUSPENSION | 60 | 13 | |
| 72786-111-03 | OXBRYTA | 90 in 1 BOTTLE, PLASTIC | TABLET, FOR SUSPENSION | 90 | 13 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 72786-111-02 | EA - Each | 72786-111 | c8c32a85-0f9e-431a-8dae-f773346fa444 | 1 | 2022-01-06 |
| 72786-111-03 | EA - Each | 72786-111 | bc6bfc64-97df-4789-98f9-4a726d43ca98 | 1 | 2022-01-06 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 72786-111 | OXBRYTA (VOXELOTOR) TABLET, FILM COATED OXBRYTA (VOXELOTOR) TABLET, FOR SUSPENSION [GLOBAL BLOOD THERAPEUTICS, INC, A SUBSIDIARY OF PFIZER INC.] | 13 | Current NDC, Legacy NDC, 2 package rows | 20231227_3c557fac-29ec-483f-b691-8a935d4decc3.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OXBRYTA | VOXELOTOR | Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. | 3c557fac-29ec-483f-b691-8a935d4decc3 | 2023-12-26 | Warnings, Adverse reactions | 216157 NDA216157 72786-111-02 72786-111 72786011102 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 2619428 | OXBRYTA 300 MG Oral Tablet | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2588074 | Oxbryta 300 MG Tablet for Oral Suspension | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2265689 | OXBRYTA 500 MG Oral Tablet | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2619427 | voxelotor 300 MG Oral Tablet | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2588070 | voxelotor 300 MG Tablet for Oral Suspension | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2265683 | voxelotor 500 MG Oral Tablet | PSN | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2619428 | voxelotor 300 MG Oral Tablet [Oxbryta] | SBD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2588074 | voxelotor 300 MG Tablet for Oral Suspension [Oxbryta] | SBD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2265689 | voxelotor 500 MG Oral Tablet [Oxbryta] | SBD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2619427 | voxelotor 300 MG Oral Tablet | SCD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2588070 | voxelotor 300 MG Tablet for Oral Suspension | SCD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2265683 | voxelotor 500 MG Oral Tablet | SCD | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2619428 | Oxbryta 300 MG Oral Tablet | SY | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2588074 | Oxbryta 300 MG Tablet for Oral Suspension | SY | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
| 2265689 | Oxbryta 500 MG Oral Tablet | SY | 3c557fac-29ec-483f-b691-8a935d4decc3 | 13 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 72786-111-02 | 72786011102 | 60 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-02) | 2021-12-17 | 0000-00-00 | No | No | Current |